Pfizer (PFE) announced positive Phase 2b results for its obesity drug, showing a 12.3% weight loss in patients over 28 weeks. The trial met its primary endpoint and had a favorable safety profile. Pfizer plans to present detailed findings at the American Diabetes Association’s Scientific Sessions in June 2026.

Following the acquisition of Metsera, Pfizer is accelerating its obesity development program with over 20 planned or ongoing studies. In 2026, the company aims to advance 10 Phase 3 trials for its obesity drug, catering to diverse patient needs with both weekly and monthly dosing regimens.

Pfizer Inc. (NYSE:PFE) is a biopharmaceutical company that discovers, develops, and sells products globally. While PFE shows investment potential, some AI stocks may offer greater upside with lower risk. For those seeking an undervalued AI stock, consider looking into the best short-term AI stock for potential growth opportunities.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss